Related Experiment Video
Updated: Apr 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Effect of prolonged dual anti-platelet therapy on reducing myocardial infarction rate after percutaneous coronary
H Q Duan1, P S Dong1, H L Wang1
1The First Affiliated Hospital of Henan University of Science and Technology, Henan, China.
Insights
Prolonged dual anti-platelet therapy after Percutaneous Coronary Intervention (PCI) significantly reduces myocardial infarction rates. Long-term treatment also lowers stent thrombosis risk without increasing serious bleeding events.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Dual anti-platelet therapy (DAPT) is crucial after Percutaneous Coronary Intervention (PCI).
- The optimal duration of DAPT remains a subject of ongoing research and clinical debate.
- This review investigates the impact of prolonged DAPT on myocardial infarction and stent thrombosis rates.
Discussion:
- Meta-analysis of randomized controlled trials indicates a significant reduction in myocardial infarction with long-term DAPT (>6 months) compared to short-term therapy (≤6 months).
- Observational studies suggest a similar trend for reduced myocardial infarction and a tendency towards lower late stent thrombosis with prolonged DAPT.
- Importantly, extended DAPT did not correlate with an increased incidence of serious bleeding events.
Key Insights:
- Long-term DAPT after PCI is associated with a statistically significant decrease in myocardial infarction rates.
- Prolonged DAPT may reduce the risk of late stent thrombosis, a critical complication post-PCI.
- The safety profile of long-term DAPT appears favorable, with no significant increase in major bleeding.
Outlook:
- Further research could explore personalized DAPT duration based on patient-specific risk factors.
- Investigating novel anti-platelet agents and combinations may offer improved efficacy and safety.
- Clinical guidelines may evolve to incorporate findings on extended DAPT duration for specific patient populations.
Abstract:
This paper aimed to review the interferential effect of prolonged dual anti-platelet therapy after Percutaneous Coronary Intervention (PCI), and the influence on reducing the myocardial infarction rate. A computer search was carried out in the relevant libraries and databases, regarding all the short-term (≤ 6 months) and long-term (> 6 months) dual anti-platelet therapies, and the curative and observational studies on the effects and safety of interventional therapy. RevMan5.1 software was used to meta-analyze the standard research. A total of 8 papers were finally selected. In the randomized controlled research, meta-analysis showed that the myocardial infarction rate of a long-term dual antiplatelet treatment group was lower than the short-term treatment group [OR=0.74, 95% CI (0.56, 0.98), P < 0.0001]. The meta-analysis of observational research showed that the myocardial infarction rate of the long-term treatment group was lower than the short-term treatment group [OR=0.7, 95% CI (0.45, 1.08), P=0.11]; the incidence rate of late stent thrombosis in the long-term treatment group was lower than in the short-term treatment group [OR=0.40, 95% CI (0.15, 1.07), P=0.07]. It can be concluded that in the long-term group (>6 months) dual anti-platelet therapy after PCI can reduce the incidence rate of myocardial infarction or death. In addition, long-term treatment can reduce the occurrence tendency of late stent thrombosis. Furthermore, in the long-term treatment group, serious bleeding events did not increase.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management